You are here

Positive Phase III Results for Linalidomide (Revlimid) in Asymptomatic Myeloma

Combo therapy with dexamethasone improves 3-year survival (August 1)

Positive results have been reported from a phase III study that evaluated lenalidomide (Revlimid, Celgene) in combination with dexamethasone followed by lenalidomide maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma. The new findings were published in the August 1 issue of the New England Journal of Medicine.

Smoldering multiple myeloma is an early, asymptomatic form of the disease characterized by a 10%-per-year risk of progression to symptomatic disease during the first 5 years.

After a median follow-up period of 40 months, the median time to progression to symptomatic disease — the study’s primary endpoint —was significantly longer in the treatment group compared with the observation group (not reached vs. 21 months, respectively; hazard ratio [HR] = 0.18; P P = 0.03). A partial response was observed in 79% of the patients in the treatment group during induction, and in 90% during the maintenance phase.

The most common grade 3 adverse events (AEs) in the treatment arm included infection (6%), asthenia (6%), neutropenia (5%), and rash (3%). No grade 4 AEs were reported. One patient had a grade 5 AE, reported as a respiratory infection.

Sources: Celgene; August 1, 2013; and NEJM; August 1, 2013.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes